세계의 에드워드 증후군 치료 시장 예측 - 치료 유형별, 유형별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Edward's Syndrome Treatment Market is accounted for $5.6 billion in 2025 and is expected to reach $8.9 billion by 2032 growing at a CAGR of 6.9% during the forecast period. Edward's Syndrome, or Trisomy 18, has no definitive cure; treatment focuses on supportive and palliative care. Medical interventions aim to manage life-threatening complications such as heart defects, feeding difficulties, and respiratory issues. Newborns may require neonatal intensive care, while long-term survivors benefit from multidisciplinary support to improve quality of life. Decisions are often guided by the severity of symptoms and family preferences. The approach emphasizes comfort, ethical considerations, and individualized care planning.

According to a 2022 review in The Journal of Pediatrics, about 50% of infants with Edward's Syndrome survive beyond the first week of life, but less than 10% live past their first year, even with intensive medical care.

Market Dynamics:

Driver:

Growing focus on palliative and comfort care

The increasing emphasis on improving the quality of life for patients with life-limiting conditions is significantly shaping the Edwards Syndrome treatment landscape. With no definitive cure currently available, the medical focus is shifting toward enhancing patient comfort through symptom management and palliative interventions. Healthcare providers are prioritizing supportive care strategies to minimize suffering and improve functional well-being, especially during neonatal and early infancy stages.

Restraint:

High mortality rate and short life expectancy

The majority of patients do not live beyond the first year of life, which impacts the scope for developing comprehensive therapeutic interventions. This short life expectancy often leads to a more conservative medical approach, with limited emphasis on aggressive treatment. Additionally, the emotional and ethical challenges surrounding decision-making for invasive procedures further limit treatment adoption.

Opportunity:

Investment in rare disease research and orphan drug designations

Strategic funding initiatives, such as orphan drug programs, are encouraging pharmaceutical companies to explore targeted therapies that cater to these underserved patient groups. Governments and regulatory authorities are offering accelerated approval pathways and financial incentives, fostering innovation in prenatal diagnostics and gene-modulating treatments. Academic institutions are also collaborating with biotech firms to explore new therapeutic angles using molecular research.

Threat:

Misinformation and lack of consistent information

Conflicting opinions on treatment protocols-particularly regarding life-sustaining interventions can lead to confusion among caregivers and healthcare professionals. Lack of centralized resources for evidence-based care impedes consensus on best practices, especially in resource-limited regions. Additionally, varying attitudes across cultures and medical systems toward managing congenital disorders exacerbate uncertainty.

Covid-19 Impact:

The COVID-19 crisis created additional difficulties for patients with rare and complex conditions like Edwards Syndrome. Disrupted access to neonatal intensive care units (NICUs) and pediatric specialists delayed timely interventions during critical care windows. Lockdowns and strained healthcare systems resulted in postponed diagnostic screenings. However, the pandemic also prompted broader adoption of telemedicine and virtual counseling, which provided families with continuity in psychosocial support and decision-making guidance.

The supportive care/palliative care segment is expected to be the largest during the forecast period

The supportive care/palliative care segment is expected to account for the largest market share during the forecast period given the absence of disease-altering therapies. These care approaches focus on easing the physical and emotional burden on patients and their families by managing feeding difficulties, respiratory issues, and pain. Hospitals are increasingly integrating interdisciplinary palliative care teams comprising neonatologists, nurses, counselors, and social workers to improve patient-centered outcomes.

The mosaic trisomy 18 segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the mosaic trisomy 18 segment is predicted to witness the highest growth rate due to comparatively better prognostic outcomes and extended survival potential. Patients with this form often exhibit milder symptoms and may benefit more from individualized treatment strategies. Advances in genetic screening and karyotyping have enhanced early detection of mosaicism, prompting clinicians to explore targeted therapeutic paths.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to improved prenatal screening infrastructure, and expanding access to neonatal care facilities. Nations such as China, India, and Japan are witnessing rising awareness of chromosomal anomalies due to national health campaigns and early intervention programs. Investments in maternal-fetal medicine and advances in non-invasive prenatal testing (NIPT) have significantly enhanced diagnostic coverage.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by robust rare disease policy frameworks and advanced healthcare infrastructure. The presence of dedicated funding channels for orphan diseases, including grants and tax credits, is accelerating research and development in this domain. The U.S. and Canada have established networks of clinical care centers that specialize in genetic disorders, offering multidisciplinary management for complex neonatal cases.

Key players in the market

Some of the key players in Edward's Syndrome Treatment Market include Thermo Fisher Scientific Inc., Stryker Corporation, Quest Diagnostics, PerkinElmer Inc., Natera, Inc., Myriad Genetics, Inc., Masimo Corporation, Koninklijke Philips N.V., Invitae Corporation, Illumina, Inc., GE HealthCare, F. Hoffmann-La Roche Ltd., Eurofins Scientific, Centogene N.V., Boston Scientific Corporation, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc and Abbott Laboratories.

Key Developments:

In June 2025, Thermo Fisher introduced the Orbitrap Astral Zoom and Orbitrap Excedion Pro mass spectrometers at the ASMS 2025 conference, offering exceptional speed, sensitivity and resolution for biopharma and omics research.

In February 2025, Thermo Fisher entered a definitive agreement to buy Solventum's Purification & Filtration division for approximately $4.1 billion, expanding its bioprocessing and biologics manufacturing capabilities.

In January 2025, Stryker agreed to acquire Inari Medical in an all-cash deal, strengthening its peripheral vascular disease treatment portfolio and enhancing endovascular procedural offerings.

Treatment Types Covered:

• Supportive Care/Palliative Care
• Potential Future Therapies
• Other Treatment Types

Types Covered:

• Full Trisomy 18
• Mosaic Trisomy 18
• Partial Trisomy 18

End Users Covered:

• Hospitals
• Clinics
• Ambulatory Surgical Centres
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Edward's Syndrome Treatment Market, By Treatment Type

• 5.1 Introduction
• 5.2 Supportive Care/Palliative Care
  • 5.2.1 Cardiac Treatment
  • 5.2.2 Assisted Feeding
  • 5.2.3 Orthopedic Treatment
  • 5.2.4 Psychosocial Support
  • 5.2.5 Early Intervention Programs
  • 5.2.6 Screening & Monitoring
• 5.3 Potential Future Therapies
  • 5.3.1 Gene Therapy
  • 5.3.2 Personalized Medicine
• 5.4 Other Treatment Types

6 Global Edward's Syndrome Treatment Market, By Type

• 6.1 Introduction
• 6.2 Full Trisomy 18
• 6.3 Mosaic Trisomy 18
• 6.4 Partial Trisomy 18

7 Global Edward's Syndrome Treatment Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Ambulatory Surgical Centres
• 7.5 Other End Users

8 Global Edward's Syndrome Treatment Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Thermo Fisher Scientific Inc.
• 10.2 Stryker Corporation
• 10.3 Quest Diagnostics
• 10.4 PerkinElmer Inc.
• 10.5 Natera, Inc.
• 10.6 Myriad Genetics, Inc.
• 10.7 Masimo Corporation
• 10.8 Koninklijke Philips N.V.
• 10.9 Invitae Corporation
• 10.10 Illumina, Inc.
• 10.11 GE HealthCare
• 10.12 F. Hoffmann-La Roche Ltd.
• 10.13 Eurofins Scientific
• 10.14 Centogene N.V.
• 10.15 Boston Scientific Corporation
• 10.16 Bio-Rad Laboratories, Inc.
• 10.17 Agilent Technologies, Inc.
• 10.18 Abbott Laboratories